Phaseline

Targets › GRPR

GRPR (Gastrin-releasing peptide receptor): drug programs, companies and trials

8 programs from 5 companies in 13 trials: 11 Phase 1, 2 Phase 2; Oncology; next expected readout Dec 2026.

Receptor for gastrin-releasing peptide (GRP). Signals via association with G proteins that activate a phosphatidylinositol-calcium second messenger system, resulting in Akt phosphorylation. (UniProt, P30550)

Open in Phaseline: the race on GRPR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Novartis[177Lu]Lu-PSMA-617
PSMA-targeted radioligand therapy with lutetium-177
FOLH1, GRPRPhase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate CancerJan 2027
Novartis[177Lu]Lu-NeoB
GRPR-targeted radioligand therapy
GRPRPhase 1Breast Cancer; Newly Diagnosed and Recurrent GlioblastomaDec 2026
First Affiliated Hospital of Fujian Medical University68Ga-G21
GRPR-targeted PET imaging agent
GRPRPhase 1Prostate Cancer (Adenocarcinoma)Dec 2026
First Affiliated Hospital of Fujian Medical University68Ga-G23
GRPR-targeted PET imaging agent
GRPRPhase 1Prostate Cancer (Adenocarcinoma)Dec 2026
Orano Med Theranostics, SAS²¹²Pb-DOTAM-GRPR1
GRPR-targeted antagonist radioimmunoconjugate with lead-212
GRPRPhase 1Cervical CancerJan 2027
Alpha-9 Oncology USA[177Lu]Lu-A9-0631
Lutetium-177 labeled GRPR-targeting peptide
GRPRPhase 1Breast CancerDec 2028
Alpha-9 Oncology USA[225Ac]Ac-A9-0642
Actinium-225 labeled GRPR-targeting peptide
GRPRPhase 1Breast CancerDec 2028
Eli LillyLY4257496
GRPR-targeting therapeutic (mechanism to be determined in Phase 1)
GRPRPhase 1Breast NeoplasmsApr 2030

Conditions

Breast Cancer (4) Metastatic Neuroendocrine Prostate Cancer (2) Prostate Cancer (Adenocarcinoma) (2) Metastatic Castration-Resistant Prostate Cancer (mCRPC) (1) Metastatic Castration-resistant Prostate Cancer (1) Newly Diagnosed and Recurrent Glioblastoma (1) Cervical Cancer (1) Breast Neoplasms (1)

Modalities

small molecule (7), mixed (1)

Companies

Novartis (2) First Affiliated Hospital of Fujian Medical University (2) Alpha-9 Oncology USA (2) Orano Med Theranostics, SAS (1) Eli Lilly (1)

Related targets

FOLH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.